Ritholtz Wealth Management decreased its position in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 39.4% during the 4th ...

Merit Financial Group LLC grew its stake in Pfizer Inc. (NYSE:PFE – Free Report) by 60.8% during the fourth quarter, ...

Many of the most devastating infectious diseases are caused by RNA viruses, and Model Medicines is working on one compound to ...

Pfizer is looking to follow its vaccine/oral antiviral combination that has proved so profitable in COVID-19 with a similar approach in respiratory syncytial virus (RSV). The drugmaker is in the ...

Datuk Dr Mohammad Agus Yusoff officially began his duties as D-G of J-KOM in the Prime Minister's Department today. Fahmi ...

Pfizer reckons it will make a whopping $22 billion in sales of its oral COVID-19 antiviral Paxlovid in 2022, with another $32 billion from its BioNTech-partnered coronavirus vaccine Comirnaty.

Historically, COVID-19 symptoms have been fevers or chills, cough, shortness of breath, cough, congestion or a runny nose, sore throat, loss of taste or smell, fatigue and body aches, headache, nausea ...

Pfizer Ltd. key Products/Revenue Segments include Pharmaceuticals, Sale of services, Scrap for the year ending 31-Mar-2024.For the quarter ended 30-09-2024, the company has reported a Standalone Total ...

"Seeing is believing," the founder of lab company Truvian told me. So I tried its tabletop blood testing device—which promises results in 30 minutes—for myself.

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.